Jefferies has upgraded Raia Drogasil (RADLY), a Brazilian pharmacy retailer, to a Buy rating even though its shares recently declined about 5.2%. The company reported earnings per share of $0.05, meeting analyst expectations, but its revenue of $2.17 billion fell short of the $2.32 billion forecast. Despite the revenue miss and stock price drop, Jefferies expects the shares to perform well going forward. RADLY currently trades around $3.80 with a market capitalization of about $6.64 billion.
For readers following Raia Drogasil (RADLY), here is Pluang's market snapshot as of Oct 19, 2026 18:21 WIB: Among 63 priced Consumer Staples-sector US stocks tradable on Pluang, 6 rose and 48 fell today. Notable movers include BTI (British American Tobacco PLC) at USD 59.45 with a -0.92% change and a typical hold time on Pluang of 88 days, LW (Lamb Weston Holdings Inc) at USD 53.11 with a -0.90% change and a typical hold time of 67 days, and PG (Procter & Gamble Co) at USD 157.89 with a -0.89% change and a typical hold time of 132 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
